EN DE

Veerhealth Care Limited (511523) Fair Value & Analysis

Other · IN · Market cap ₹52.0M

VC Veerhealth Care Limited 511523 · BSE
Price₹48.02
Fair Value₹86.72
Upside+80.6%
Quality50/100
Watch Veerhealth Care Limited for free, get notified when fair value or trend changes. Watch for free

Strengths

Trades 45% below our fair value of ₹86.72
Ranks above peers (8/10)

Risks

!Expensive Growth (revenue 5y +25.2 %/yr)
!Thin margins · 0.0% net margin
!Low debt · negative free cash flow
!Evidence only medium, so the estimate is less certain
Expensive Growth (revenue 5y +25.2 %/yr)
Thin margins · 0.0% net margin
Low debt · negative free cash flow
Ranks above peers (8/10)
Evidence: Medium Range ₹65.04 – ₹108.41 Share as image

Fair value as of: Aug 25, 2026

From 14 valuation models · updated yesterday

Fair value updated Aug 25, 2026, revised from ₹83.36 to ₹86.72 (+4.0%) since Aug 13, 2026. Share price +15.7% over the past month.

A solid business, trading 45% below our fair value.

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Track Veerhealth Care Limited and get told automatically when its fair value or trend turns, plus fair value for all 35,000+ stocks. 14 days of Pro free, no card.

What matters now

  • The price is below even our cautious bear case (₹65.04). The market is more pessimistic than our downside scenario.
  • Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

₹49.00 ₹4.26 Fair Value ₹86.72 Apr 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 25, 2026.

How to read this chart

60‑month range ₹4.26 – ₹49.00 · fair‑value band ₹65.04 – ₹108.41 · the ₹48.02 price screens below the ₹86.72 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 25, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Veerhealth Care Limited (511523) currently trades at ₹48.02, while our model-based Fair Value estimate is ₹86.72, implying the stock looks roughly 80.6% undervalued today. The Quality Score stands at 50/100 (solid quality), in the Other sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Net debt stands at ₹41.2M. The stock trades on a trailing P/E of 13.2 (as of Aug 25, 2026). Fundamentals as of Aug 25, 2026

Our scenario range runs from ₹65.04 (bear case) to ₹108.41 (bull case); at ₹48.02, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 187% above its 52-week low. For context, the median of 10 Other peers we cover trades at -24% fair-value upside, at 81%, 511523 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
ROIC Compounder ₹38.69 ₹47.01 ₹53.77 72
Growth-Adj P/E ₹138.51 ₹197.87 ₹257.23 68
P/E Multiple ₹64.04 ₹85.39 ₹106.74 63
All 14 models by family
Earnings-Based
Graham-Dodd ₹34.16 ₹238.20 ₹334.28 54
Lynch FV ₹110.62 ₹158.02 ₹205.43 50
PEG = 1.0 ₹110.62 ₹158.02 ₹205.43 46
EPV ₹38.69 ₹47.01 ₹53.77 59
Multiples
P/E Multiple ₹64.04 ₹85.39 ₹106.74 63
P/S Multiple ₹64.04 ₹85.39 ₹106.74 58
P/B Multiple ₹64.04 ₹85.39 ₹106.74 55
EV/EBIT ₹82.62 ₹120.38 ₹158.14 53
EV/EBITDA ₹139.68 ₹196.46 ₹253.25 54
EV/Revenue ₹67.51 ₹109.59 ₹151.67 43
Asset-Based
NCAV (Graham) ₹105.83 ₹141.81 ₹211.66 50
Economic Profit
Residual Income ₹135.02 ₹123.92 ₹86.49 61
ROIC Compounder ₹38.69 ₹47.01 ₹53.77 72
Growth Earnings
Growth-Adj P/E ₹138.51 ₹197.87 ₹257.23 68

Widest divergence: Growth Earnings (₹197.87) versus Economic Profit (₹47.01). Highest evidence: ROIC Compounder (72).

Notify me when 511523 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 13.2 as of Aug 25, 2026
EPS (TTM) ₹0.5678
Free cash flow −₹6.6M FY2026
Net debt ₹41.2M FY2026

Figures from reported company fundamentals · as of Aug 25, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 50/100

Of which business quality 47 · Market factors (momentum, volatility) 88

Profitability 30
Margins and returns on capital today
Quality Growth 62
Are margins and returns improving?
Cashflow 40
Earnings quality: real cash, not paper profit
Fin. Strength 41
Balance sheet, leverage, solvency risk
Investment 39
Disciplined investing over empire-building
Low Volatility 65
Calm price path (market factor)
Momentum 100
Price trend over the last 3–12 months (market factor)
52W Momentum 96
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Veerhealth Care Limited manufactures and markets ayurvedic medicines in India. The company also offers tablets, syrups, ointments, powders, oils, shampoos, cosmetics, and toothpastes. It also exports its products. The company was formerly known as Niyati Industries Limited and changed its name to Veerhealth Care Limited in September 2013.

Full company description

Veerhealth Care Limited manufactures and markets ayurvedic medicines in India. The company also offers tablets, syrups, ointments, powders, oils, shampoos, cosmetics, and toothpastes. It also exports its products. The company was formerly known as Niyati Industries Limited and changed its name to Veerhealth Care Limited in September 2013. Veerhealth Care Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Veerhealth Care Limited reported revenue of ₹325M in FY2026 versus ₹96.3M in FY2022, a compound +35.5%/yr. Reported net income was ₹5.4M in FY2026.

Growth Quality 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2026)
₹325M
Latest YoY
+94.9%
Avg. revenue growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+34.8%
Avg. revenue growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+25.2%
Avg. revenue growth/yr (12Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+22.0%
Value creation/yr (5Y) Earnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
−5.8% (-5.8 + 0.0)
Revenue +35.5%/yr
FY22 ₹96.3M
FY23 ₹133M
FY24 ₹132M
FY25 ₹167M
FY26 ₹325M
Net income
FY22 −₹736K
FY23 ₹15.8M
FY24 ₹4.1M
FY25 ₹3.9M
FY26 ₹5.4M

Watch 511523: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Veerhealth Care Limited Fair Value". https://www.fairvalue-calculator.com/stock/511523

Peer Group

Other · 308 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 50 · Below median
Fair Value upside +81% · Top 25%
Return on assets 0% · Top 25%
Net margin (TTM) 0% · Above median
Operating margin (TTM) 0% · Above median
Revenue growth 0% · Top 25%
Debt / equity 0.17× · Higher than median

Valuation Multiples vs Other median · lower = cheaper

P/E (TTM) 13.2× · Cheaper than median
EV/EBITDA 1.9× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE100 · sector 0
FUTURE0 · sector 0
PAST0 · sector 0
HEALTH92 · sector 98
DIVIDEND0 · sector 25

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Other stocks, each showing price versus our Fair Value estimate (as of Aug 25, 2026).

Stock Price Fair Value vs Fair Value
Federal Home Loan Mortgage Corporation FREJO $15.58 $51.90 +233%
533278 533278 ₹406.50 ₹660.78 +63%
Nestl?? India Limited 500790 ₹1,470 ₹191.93 -87%
ITC Limited 500875 ₹279.50 ₹212.74 -24%
Wipro Limited 507685 ₹183.80 ₹193.38 +5%
540376 540376 ₹4,054 ₹1,542 -62%
540777 540777 ₹537.50 ₹149.72 -72%
Lupin Limited 500257 ₹2,265 ₹1,983 -12%
Dabur India Limited 500096 ₹413.80 ₹122.93 -70%
540719 540719 ₹1,835 ₹872.41 -52%

Compare Veerhealth Care Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Fama-French 3-Factor Model Calculator Run the Fama-French 3-factor model in seconds: expected return from the market, size and value factors - free, with formula, betas and an example. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Veerhealth Care Limited (511523) overvalued or undervalued?
As of Aug 25, 2026, our model estimates a fair value of ₹86.72 versus a price of ₹48.02, about +81% (undervalued).
What is the fair value of 511523?
Our model-based fair value for Veerhealth Care Limited is ₹86.72 (as of Aug 25, 2026), built from audited fundamentals. The current price: ₹48.02.
What is the quality score of 511523?
Veerhealth Care Limited has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the net profit margin of 511523?
The net profit margin of Veerhealth Care Limited is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Veerhealth Care Limited and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.